GSK plc reported a strong 2023 performance with sales reaching £30.3 billion, up 5% overall and 14% excluding COVID-19 solutions. The company anticipates 2024 sales growth of 5-7% and increased dividends with notable growth in vaccine sales, particularly Shingrix and Arexvy.